Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Arrhythmias

  Free Subscription


Articles published in Eur Heart J

Retrieve available abstracts of 92 articles:
HTML format
Text format



Single Articles


    February 2019
  1. VAN DEN BERG MP, Mulder BA, Klaassen SHC, Maass AH, et al
    Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis.
    Eur Heart J. 2019 Feb 8. pii: 5310346. doi: 10.1093.
    PubMed     Text format     Abstract available


  2. SCHWARTZ PJ, Gnecchi M, Dagradi F, Castelletti S, et al
    From patient-specific induced pluripotent stem cells to clinical translation in long QT syndrome Type 2.
    Eur Heart J. 2019 Feb 6. pii: 5307938. doi: 10.1093.
    PubMed     Text format     Abstract available


  3. TRENKWALDER T, Schunkert H
    Risk of atrial fibrillation in big people under the magnifying glass of G. J. Mendel.
    Eur Heart J. 2019 Feb 5. pii: 5306113. doi: 10.1093.
    PubMed     Text format    


  4. TIKKANEN E, Gustafsson S, Knowles JW, Perez M, et al
    Body composition and atrial fibrillation: a Mendelian randomization study.
    Eur Heart J. 2019 Feb 5. pii: 5306116. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2019
  5. BUNCH JT, Woller SC
    Saving the brain from catheter ablation of atrial fibrillation: the role of pre- and peri-procedural anticoagulation.
    Eur Heart J. 2019 Jan 31. pii: 5305045. doi: 10.1093.
    PubMed     Text format    


  6. VERKERK AO, Remme CA
    Down the rabbit hole: deciphering the short QT syndrome.
    Eur Heart J. 2019 Jan 27. pii: 5303207. doi: 10.1093.
    PubMed     Text format    


  7. GOLDHABER SZ, Piazza G
    Fine-tuning the decision to initiate anticoagulation in atrial fibrillation by accounting for age and cardiovascular comorbidities.
    Eur Heart J. 2019 Jan 25. pii: 5301477. doi: 10.1093.
    PubMed     Text format    


  8. KHAN AA, Lip GYH
    Non-vitamin K antagonist oral anticoagulants beyond atrial fibrillation: what did we learn from COMPASS and COMMANDER-HF?
    Eur Heart J. 2019 Jan 21. pii: 5298544. doi: 10.1093.
    PubMed     Text format    


  9. BORIANI G, Ruff CT, Kuder JF, Shi M, et al
    Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial.
    Eur Heart J. 2019 Jan 8. pii: 5280832. doi: 10.1093.
    PubMed     Text format     Abstract available


  10. CHUA W, Purmah Y, Cardoso VR, Gkoutos GV, et al
    Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation.
    Eur Heart J. 2019 Jan 7. pii: 5270657. doi: 10.1093.
    PubMed     Text format     Abstract available


  11. KIM TH, Yang PS, Yu HT, Jang E, et al
    Effect of hypertension duration and blood pressure level on ischaemic stroke risk in atrial fibrillation: nationwide data covering the entire Korean population.
    Eur Heart J. 2019 Jan 4. pii: 5273478. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. CHAO TF, Lip GYH, Lin YJ, Chang SL, et al
    Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities.
    Eur Heart J. 2019 Jan 2. pii: 5272355. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2018
  13. YU HT, Shim J, Park J, Kim TH, et al
    When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study.
    Eur Heart J. 2018 Dec 27. pii: 5263768. doi: 10.1093.
    PubMed     Text format     Abstract available


  14. WANG KL, Lopes RD, Patel MR, Buller HR, et al
    Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.
    Eur Heart J. 2018 Dec 22. pii: 5255630. doi: 10.1093.
    PubMed     Text format     Abstract available


  15. CHAO TF, Chen SA, Ruff CT, Hamershock RA, et al
    Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial.
    Eur Heart J. 2018 Dec 22. pii: 5258031. doi: 10.1093.
    PubMed     Text format     Abstract available


  16. RICHTER S, Di Biase L, Hindricks G
    Atrial fibrillation ablation in heart failure.
    Eur Heart J. 2018 Dec 14. pii: 5248225. doi: 10.1093.
    PubMed     Text format     Abstract available


  17. KILLU AM, Granger CB, Gersh BJ
    Risk stratification for stroke in atrial fibrillation: a critique.
    Eur Heart J. 2018 Dec 1. pii: 5224504. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2018
  18. STEFFEL J, Potpara TS
    Challenges in clinical decision-making on concomitant drug therapies in patients with atrial fibrillation taking oral anticoagulants.
    Eur Heart J. 2018 Nov 29. pii: 5219661. doi: 10.1093.
    PubMed     Text format    


  19. ODENING KE, Bodi I, Franke G, Rieke R, et al
    Transgenic short-QT syndrome 1 rabbits mimic the human disease phenotype with QT/action potential duration shortening in the atria and ventricles and increased ventricular tachycardia/ventricular fibrillation inducibility.
    Eur Heart J. 2018 Nov 28. pii: 5212713. doi: 10.1093.
    PubMed     Text format     Abstract available


  20. LUSCHER TF
    Dangerous encounters: triggers of fatal ventricular arrhythmias and safety of interventional treatment strategies.
    Eur Heart J. 2018;39:3909-3912.
    PubMed     Text format    


  21. SIONTIS KC, Yao X, Noseworthy PA
    Atrial fibrillation in heart failure syndromes: does it matter more in some than in others?
    Eur Heart J. 2018 Nov 20. pii: 5193438. doi: 10.1093.
    PubMed     Text format    


  22. NISHIMURA M, Maisel AS
    Biomarkers: a window into the pathophysiology of atrial fibrillation in heart failure with reduced vs. preserved ejection fraction.
    Eur Heart J. 2018;39:3876-3878.
    PubMed     Text format    


  23. GOLWALA H, Cannon CP, Bhatt DL
    Reply to: Dual vs. triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Eur Heart J. 2018 Nov 5. pii: 5161202. doi: 10.1093.
    PubMed     Text format    


  24. GRAGNANO F, Calabro P, Valgimigli M
    Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention?
    Eur Heart J. 2018 Nov 5. pii: 5161206. doi: 10.1093.
    PubMed     Text format    


    October 2018
  25. BOERSMA LVA
    Biventricular pacing after AV-node ablation for atrial fibrillation with heart failure: something old and something new, future standard, or just for the few?
    Eur Heart J. 2018 Oct 25. pii: 5145027. doi: 10.1093.
    PubMed     Text format    


  26. JOHN RM, Michaud GF, Stevenson WG
    Atrial fibrillation hospitalization, mortality, and therapy.
    Eur Heart J. 2018 Oct 16. pii: 5133619. doi: 10.1093.
    PubMed     Text format    


  27. ZAFRIR B, Lund LH, Laroche C, Ruschitzka F, et al
    Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry.
    Eur Heart J. 2018 Oct 15. pii: 5133012. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2018
  28. CALKINS H
    A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy: is this too good to be true?
    Eur Heart J. 2018 Sep 17. pii: 5098639. doi: 10.1093.
    PubMed     Text format    


  29. CHATTERJEE D, Fatah M, Akdis D, Spears DA, et al
    An autoantibody identifies arrhythmogenic right ventricular cardiomyopathy and participates in its pathogenesis.
    Eur Heart J. 2018 Sep 17. pii: 5098642. doi: 10.1093.
    PubMed     Text format     Abstract available


    August 2018
  30. BRIGNOLE M, Pokushalov E, Pentimalli F, Palmisano P, et al
    A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS.
    Eur Heart J. 2018 Aug 26. pii: 5078460. doi: 10.1093.
    PubMed     Text format     Abstract available


  31. SANTEMA BT, Kloosterman M, Van Gelder IC, Mordi I, et al
    Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction.
    Eur Heart J. 2018 Aug 22. pii: 5077588. doi: 10.1093.
    PubMed     Text format     Abstract available


  32. GUTMAN SJ, Costello BT, Papapostolou S, Voskoboinik A, et al
    Reduction in mortality from implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy patients is dependent on the presence of left ventricular scar.
    Eur Heart J. 2018 Aug 10. pii: 5070406. doi: 10.1093.
    PubMed     Text format     Abstract available


  33. FREEDMAN B
    Major progress in anticoagulant uptake for atrial fibrillation at last: does it translate into stroke prevention?
    Eur Heart J. 2018 Aug 10. pii: 5070412. doi: 10.1093.
    PubMed     Text format    


  34. POLOVINA M, Hindricks G, Maggioni A, Piepoli M, et al
    Association of metabolic syndrome with non-thromboembolic adverse cardiac outcomes in patients with atrial fibrillation.
    Eur Heart J. 2018 Aug 7. pii: 5067645. doi: 10.1093.
    PubMed     Text format     Abstract available


  35. STEINBECK G, Sinner MF, Lutz M, Muller-Nurasyid M, et al
    Incidence of complications related to catheter ablation of atrial fibrillation and atrial flutter: a nationwide in-hospital analysis of administrative data for Germany in 2014.
    Eur Heart J. 2018 Aug 1. pii: 5063863. doi: 10.1093.
    PubMed     Text format     Abstract available


    July 2018
  36. PATHAK RK, Sanders P, Deo R
    Primary prevention implantable cardioverter-defibrillator and opportunities for sudden cardiac death risk assessment in non-ischaemic cardiomyopathy.
    Eur Heart J. 2018 Jul 17. pii: 5055243. doi: 10.1093.
    PubMed     Text format     Abstract available


  37. COWAN JC, Wu J, Hall M, Orlowski A, et al
    A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation.
    Eur Heart J. 2018 Jul 5. pii: 5049393. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2018
  38. MAROTT JL, Skielboe AK, Dixen U, Friberg JB, et al
    Increasing population height and risk of incident atrial fibrillation: the Copenhagen City Heart Study.
    Eur Heart J. 2018 Jun 28. pii: 5046683. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2018
  39. FRIEDMAN DJ, Granger CB
    Uninterrupted apixaban for atrial fibrillation ablation is a reasonable alternative, but what is the significance of silent cerebral infarctions?
    Eur Heart J. 2018 May 19. pii: 4999868. doi: 10.1093.
    PubMed     Text format    


    April 2018
  40. FANAROFF AC, Steffel J, Alexander JH, Lip GYH, et al
    Stroke prevention in atrial fibrillation: re-defining 'real-world data' within the broader data universe.
    Eur Heart J. 2018 Apr 23. pii: 4982606. doi: 10.1093.
    PubMed     Text format     Abstract available


  41. LUSCHER TF
    Atrial fibrillation and arrhythmias: novel risk assessment, proper anticoagulation, and ablation.
    Eur Heart J. 2018;39:1317-1321.
    PubMed     Text format    


  42. CONEN D
    Epidemiology of atrial fibrillation.
    Eur Heart J. 2018;39:1323-1324.
    PubMed     Text format    


  43. GOLWALA HB, Cannon CP, Steg PG, Doros G, et al
    Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials.
    Eur Heart J. 2018 Apr 13. pii: 4970508. doi: 10.1093.
    PubMed     Text format     Abstract available


  44. EZEKOWITZ MD, Pollack CV Jr, Halperin JL, England RD, et al
    Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial.
    Eur Heart J. 2018 Apr 6. pii: 4963487. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2018
  45. POKORNEY SD, Daubert JP
    Atrial fibrillation ablation alone or atrial fibrillation ablation plus an antiarrhythmic drug?
    Eur Heart J. 2018 Mar 27. pii: 4955289. doi: 10.1093.
    PubMed     Text format    


  46. KIRCHHOF P, Haeusler KG, Blank B, De Bono J, et al
    Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation.
    Eur Heart J. 2018 Mar 20. pii: 4943979. doi: 10.1093.
    PubMed     Text format     Abstract available


  47. STEFFEL J, Verhamme P, Potpara TS, Albaladejo P, et al
    The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
    Eur Heart J. 2018 Mar 17. pii: 4942493. doi: 10.1093.
    PubMed     Text format     Abstract available


  48. WALDMANN V, Bougouin W, Karam N, Dumas F, et al
    Characteristics and clinical assessment of unexplained sudden cardiac arrest in the real-world setting: focus on idiopathic ventricular fibrillation.
    Eur Heart J. 2018 Mar 16. pii: 4939309. doi: 10.1093.
    PubMed     Text format     Abstract available


  49. HASEGAWA K, Kaseno K, Aiki T, Tada H, et al
    Left atrial sarcoidosis as a substrate for peri-mitral atrial flutter: an unusual, underlying atrial disease.
    Eur Heart J. 2018 Mar 15. pii: 4938722. doi: 10.1093.
    PubMed     Text format    


    February 2018
  50. LANCELLOTTI P, Galderisi M
    Prediction of ischaemic stroke in non-valvular atrial fibrillation if advanced echocardiography plays the game.
    Eur Heart J. 2018 Feb 9. pii: 4847811. doi: 10.1093.
    PubMed     Text format    


  51. RIENSTRA M, Hobbelt AH, Alings M, Tijssen JGP, et al
    Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial.
    Eur Heart J. 2018 Feb 1. pii: 4786620. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2018
  52. MAHAJAN R, Perera T, Elliott AD, Twomey DJ, et al
    Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis.
    Eur Heart J. 2018 Jan 10. pii: 4797540. doi: 10.1093.
    PubMed     Text format     Abstract available


  53. HEALEY JS
    The winding path towards rationale anti-thrombotic therapy to prevent stroke in patients with atrial fibrillation.
    Eur Heart J. 2018 Jan 9. pii: 4796907. doi: 10.1093.
    PubMed     Text format    


  54. LIP GYH, Lane DA, Potpara TS
    Innovative strategies to improve adherence to non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation.
    Eur Heart J. 2018 Jan 6. pii: 4791955. doi: 10.1093.
    PubMed     Text format    


  55. DESTEGHE L, Vijgen J, Koopman P, Dilling-Boer D, et al
    Telemonitoring-based feedback improves adherence to non-vitamin K antagonist oral anticoagulants intake in patients with atrial fibrillation.
    Eur Heart J. 2018 Jan 2. pii: 4782504. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2017
  56. LEUNG M, van Rosendael PJ, Abou R, Ajmone Marsan N, et al
    Left atrial function to identify patients with atrial fibrillation at high risk of stroke: new insights from a large registry.
    Eur Heart J. 2017 Dec 28. pii: 4781364. doi: 10.1093.
    PubMed     Text format     Abstract available


  57. VERHEUGT FWA, Gao H, Al Mahmeed W, Ambrosio G, et al
    Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry.
    Eur Heart J. 2017 Dec 20. pii: 4769347. doi: 10.1093.
    PubMed     Text format     Abstract available


  58. POKORNEY SD, Granger CB
    Traumatic injury: another unjustified reason to stop oral anticoagulation for atrial fibrillation.
    Eur Heart J. 2017 Dec 13. pii: 4735276. doi: 10.1093.
    PubMed     Text format    


  59. DUYTSCHAEVER M, Demolder A, Phlips T, Sarkozy A, et al
    PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial.
    Eur Heart J. 2017 Dec 2. pii: 4683714. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2017
  60. SPOSATO LA, Lopes RD
    Oral anticoagulation: a step toward solving the puzzle of dementia related to atrial fibrillation?
    Eur Heart J. 2017 Nov 27. pii: 4665696. doi: 10.1093.
    PubMed     Text format    


  61. PICCINI JP, Kirchhof P
    Improving outcomes after catheter ablation of atrial fibrillation: better patient selection, better procedure, or both?
    Eur Heart J. 2017 Nov 22. pii: 4652880. doi: 10.1093.
    PubMed     Text format    


  62. STAERK L, Fosbol EL, Lamberts M, Bonde AN, et al
    Resumption of oral anticoagulation following traumatic injury and risk of stroke and bleeding in patients with atrial fibrillation: a nationwide cohort study.
    Eur Heart J. 2017 Nov 18. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2017
  63. FRIBERG L, Rosenqvist M
    Less dementia with oral anticoagulation in atrial fibrillation.
    Eur Heart J. 2017 Oct 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  64. LIP GYH, Lane DA, Sarwar S
    Streamlining primary and secondary care management pathways for stroke prevention in atrial fibrillation.
    Eur Heart J. 2017;38:2980-2982.
    PubMed     Text format    


  65. HIJAZI Z, Oldgren J, Lindback J, Alexander JH, et al
    A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score.
    Eur Heart J. 2017 Oct 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  66. DELISLE BP, January CT
    Advancing precision medicine for the treatment of long-QT syndrome type 2: shedding light on lumacaftor.
    Eur Heart J. 2017 Oct 11. doi: 10.1093.
    PubMed     Text format    


    September 2017
  67. KOTECHA D, Kirchhof P
    ESC Apps for Atrial Fibrillation.
    Eur Heart J. 2017;38:2643-2645.
    PubMed     Text format    


  68. LUSCHER TF
    Risk factors and consequences of atrial fibrillation: genetics, blood pressure, working hours, and cognitive decline.
    Eur Heart J. 2017;38:2573-2575.
    PubMed     Text format    


  69. KIRCHHOF P, Sanders P
    My atrial fibrillation is not your atrial fibrillation.
    Eur Heart J. 2017;38:2608-2611.
    PubMed     Text format    


  70. MAHMOODI BK, Boersma LV
    Do long working hours predispose to atrial fibrillation?
    Eur Heart J. 2017;38:2629-2631.
    PubMed     Text format    


  71. KIVIMAKI M, Nyberg ST, Batty GD, Kawachi I, et al
    Long working hours as a risk factor for atrial fibrillation: a multi-cohort study.
    Eur Heart J. 2017;38:2621-2628.
    PubMed     Text format     Abstract available


    August 2017
  72. PALLISGAARD JL, Gislason GH, Hansen J, Johannessen A, et al
    Temporal trends in atrial fibrillation recurrence rates after ablation between 2005 and 2014: a nationwide Danish cohort study.
    Eur Heart J. 2017 Aug 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  73. KIRCHHOF P, Schroeder S
    NOACs in Atrial Fibrillation.
    Eur Heart J. 2017;38:2382-2385.
    PubMed     Text format    


    July 2017
  74. MEHTA A, Ramachandra CJA, Singh P, Chitre A, et al
    Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model.
    Eur Heart J. 2017 Jul 21. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2017
  75. LEE SS, Ae Kong K, Kim D, Lim YM, et al
    Clinical implication of an impaired fasting glucose and prehypertension related to new onset atrial fibrillation in a healthy Asian population without underlying disease: a nationwide cohort study in Korea.
    Eur Heart J. 2017 Jun 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  76. HUANG H, Darbar D
    Genetic heterogeneity of atrial fibrillation susceptibility loci across racial or ethnic groups.
    Eur Heart J. 2017 Jun 14. doi: 10.1093.
    PubMed     Text format    


  77. DIENER HC
    Does atrial fibrillation lead to cognitive decline and dementia?
    Eur Heart J. 2017 Jun 14. doi: 10.1093.
    PubMed     Text format    


    May 2017
  78. LUSCHER TF
    Gender issues in arrhythmias: from atrial fibrillation to CRT and arrhythmogenic ventricular cardiomyopathy.
    Eur Heart J. 2017;38:1443-1446.
    PubMed     Text format    


    April 2017
  79. SINGH-MANOUX A, Fayosse A, Sabia S, Canonico M, et al
    Atrial fibrillation as a risk factor for cognitive decline and dementia.
    Eur Heart J. 2017 Apr 29. doi: 10.1093.
    PubMed     Text format     Abstract available


  80. LEE JY, Kim TH, Yang PS, Lim HE, et al
    Korean atrial fibrillation network genome-wide association study for early-onset atrial fibrillation identifies novel susceptibility loci.
    Eur Heart J. 2017 Apr 27. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2017
  81. RAHIMI K
    Subclinical atrial fibrillation in need of more assertive evidence.
    Eur Heart J. 2017 Mar 31. doi: 10.1093.
    PubMed     Text format    



  82. Corrigendum to: 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS'.
    Eur Heart J. 2017 Mar 27. doi: 10.1093.
    PubMed     Text format    


  83. CAMM AJ, Savelieva I
    Female gender as a risk factor for stroke associated with atrial fibrillation.
    Eur Heart J. 2017 Mar 27. doi: 10.1093.
    PubMed     Text format    


  84. LUSCHER TF
    Atrial fibrillation and thrombo- embolism: anticoagulants or devices?
    Eur Heart J. 2017;38:839-842.
    PubMed     Text format    


  85. ABDUL-RAHIM AH, Perez AC, MacIsaac RL, Jhund PS, et al
    Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials.
    Eur Heart J. 2017;38:742-750.
    PubMed     Text format     Abstract available


  86. BAX JJ, Delgado V, Sogaard P, Singh JP, et al
    Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: a subanalysis of the randomized EchoCRT trial.
    Eur Heart J. 2017;38:720-726.
    PubMed     Text format     Abstract available


  87. VAN GELDER IC, Healey JS, Crijns HJ, Wang J, et al
    Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT.
    Eur Heart J. 2017 Mar 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2017
  88. SHUN-SHIN MJ, Zheng SL, Cole GD, Howard JP, et al
    Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in the 11 trials.
    Eur Heart J. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  89. AKDIS D, Saguner AM, Shah K, Wei C, et al
    Sex hormones affect outcome in arrhythmogenic right ventricular cardiomyopathy/dysplasia: from a stem cell derived cardiomyocyte-based model to clinical biomarkers of disease outcome.
    Eur Heart J. 2017 Feb 18. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2017
  90. REINER MF, Breitenstein A, Holy EW, Glanzmann M, et al
    Ticagrelor, but not clopidogrel active metabolite, displays antithrombotic properties in the left atrial endocardium.
    Eur Heart J. 2017 Jan 8. pii: ehw578. doi: 10.1093.
    PubMed     Text format     Abstract available


  91. GAL P, Marrouche NF
    Magnetic resonance imaging of atrial fibrosis: redefining atrial fibrillation to a syndrome.
    Eur Heart J. 2017;38:14-19.
    PubMed     Text format     Abstract available


    September 2016
  92. PICCINI JP, Sievert H, Patel MR
    Left atrial appendage occlusion: rationale, evidence, devices, and patient selection.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Arrhythmias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: